옵션 체인은 다양한 행사가격과 만기일에 대한 IperionX의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 IperionX에 대한 시장 심리를 평가합니다..

IperionX (NASDAQ:IPX) 주식, 옵션 체인

IperionX Ltd produces titanium critical minerals, titanium powders, and titanium end products for various industries. The company's breakthrough titanium technologies have demonstrated the potential to produce titanium products that are sustainable, recyclable, and have low carbon intensity. IperionX is producing titanium metal powders from titanium scrap at its operational pilot facility in Utah, It also owns a titan critical minerals project, the Titan Project, covering over 11,000 acres of critical minerals that include titanium, rare earth elements, silica sand, and zircon in Tennessee, United States.

mining shutter

Earnings

Commodities

CENX

USAP

2024년 5월 1일의 주요 소식: 1. 이페리온X(NASDAQ:IPX)와 베가스 패스너 매뉴팩처링(Vegas Fastener Manufacturing)은 미국 육군 지상 차량 시스템 센터를 포함한 주요 부문을 위한 티타늄 합금 패스너 및 정밀 부품을 개발 및 제조하기 위해 파트너십을 맺었다.

수요일 주요 광업 뉴스: 이페리온X, 유니버설 스테인리스, 센추리 알루미늄, 라이어슨

Mining,Cart,In,Silver,,Gold,,Copper,Mine

Global

AAUKF

GATO

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

2024년 4월 26일의 주요 뉴스: 앵글로 아메리칸(OTC:AAUKF)은 BHP 그룹(NYSE:BHP)의 390억 달러 규모의 전체 주식 인수 입찰을 &#39;매우 매력이 없고&#39; 저평가됐다며 거부했다.

금요일 주요 광업 뉴스: 앵글로 아메리칸, 가토스 실버, 이페리온X, 하이크로프트

IONR

2024년 4월 15일 주요 뉴스: 1. 피드몬트 리튬 (NASDAQ:PLL)는 가스통(Gaston) 카운티의 캐롤라이나 리튬(Carolina Lithium) 프로젝트에 대한 채광 허가에 대해 노스캐롤라이나 환경부로부터 승인을 받니다. 2021년 8월부터 철저한 검토를 거쳐 발급된 이번 허가로, 이 사이트의 건설, 운영 및 복구가 가능해졌다. 

월요일 주요 광업 뉴스: 피드몬트, U.S. 스틸, 아이오니어, 이페리온엑스

IperionX Limited - American Depositary Share

IperionX Ltd

Tachyon Protocol

Impax Asset Management Group PLC

Inpex Corp

INFLECTION PT ACQUISITION CORP II USD UNITS CONSISTING ONE CL A ORD SH & ONE-HALF OF ONE RED

<ul>
<li>The financing is led by Michael Hess, Chief Investment Officer of Hess Capital, and Brian Paes-Braga, Managing Partner at SAF Group and Head of SAF Growth</li>
<li>It comprises a Registered Direct Offering at $3.00 per share and warrants exercisable at $4.50 per share, with mandatory exercise if shares trade above $7.00 per share for 20 consecutive days</li>
<li>Proceeds are expected to be sufficient to fund operations through the potential issuance of a commercial recovery permit</li>
<li>The investor group brings decades of experience in large-scale resource development and deep global relationships across industry, government and capital markets</li>
</ul>
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) ("TMC" or the "Company"), a leading explorer of the world's largest undeveloped resource of critical metals essential to energy, defense, manufacturing, and infrastructure, today announced a $37 million registered direct offering through a securities purchase agreement with Michael Hess and his affiliated private investment vehicles. Brian Paes-Braga, Managing Partner at SAF Group and a long-time supporter of TMC, is participating alongside Mr. Hess in the offering. An existing strategic TMC investor is also participating in the offering.
Pursuant to the agreement, TMC will issue 12.3 million common shares at $3.00 per share, with each share accompanied by a Class C warrant to purchase one additional share at an exercise price of $4.50 per share. The warrants have a three-year term and include a compulsory exercise provision if the stock trades above $7.00 per share for 20 consecutive trading days. Gross proceeds are expected to total approximately $37 million before expenses. Proceeds will be used to advance the Company's commercial development plans and for general corporate purposes and are expected to be sufficient to fund operations through the potential issuance of a commercial recovery permit. The offering is expected to close on or about May 22, 2025, subject to customary closing conditions.

News

Offerings

TMC The Metals Company Announces $37M Strategic Financing Through Registered Direct Offering At $3.00/Share With $4.50 Warrants, Providing Capital To Fund Operations Through Potential Commercial Recovery Permit

Maxim Group analyst Jason McCarthy initiates coverage on ProMIS Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) with a Buy rating and announces Price Target of $3.

Price Target

Initiation

Analyst Ratings

Maxim Group Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $3

Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) announced today that it intends to offer $500 million aggregate principal amount of senior unsecured notes due 2033 issued by its subsidiary Crown Americas LLC, subject to market conditions.
Crown intends to use the net proceeds from the offering, together with cash on hand and borrowings under Crown's senior secured revolving credit facility, to repay the 4.750% senior notes due 2026, and to pay related fees and expenses.

Crown Holdings Intends To Offer $500M Senior Unsecured Notes Due 2033

NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence &amp; Robotics Initiatives as It Awaits Italian Government ‘Golden Power' Approval
NUBURU, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>), a leader in high-power blue laser technology, announced today that it has filed with the Securities and Exchange Commission a Form S-3 Registration statement for $100 million. This strategic move is designed to provide the company with the necessary capital to facilitate the ongoing acquisition plan and successfully relaunch its Blue Laser technology business unit.
As reaffirmed in the latest communications, NUBURU aims at completing the purchase of defense and security businesses, referred to herein as the "Defense &amp; Security Hub" for confidentiality reasons. This hub will focus on delivering cutting-edge products tailored for defense applications ("DefenseTech Business") while providing robust operational resilience solutions through a software-as-a-service model ("SaaS Business"). Once finalized, these acquisitions are projected to contribute over $50 million in revenue for NUBURU in 2025, subject to U.S. GAAP accounting and the effective date of the closing.
The DefenseTech Business acquisition involves a well established scale-up company which is subject to governmental review under Italy's "golden power," which allows the Italian government to screen and potentially block foreign investments in sectors deemed critical to national security. This regulatory assessment, which it's expected to be completed by end of June, aims to ensure that investments align with the national interest, particularly in areas such as defense and critical technologies.
NUBURU is also actively advancing its Transformation Plan, which emphasizes the adoption of exponential technologies, including artificial intelligence (AI) and robotics by leveraging the strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>), with particular reference to the SaaS Business and the Blue-Laser technology go-to-market.

BURU

COEP

NUBURU Advances $100M Capital Raise And Strategic Acquisition Of Defense & Security Hub Pending Italian 'Golden Power' Approval, Aiming To Drive Over $50M In 2025 Revenue While Relaunching Blue Laser Business

Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 3.13 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $895.65 thousand which missed the analyst consensus estimate of $725.00 million by 99.88 percent. This is a 38.51 percent increase over sales of $646.63 thousand the same period last year.

Earnings Misses

NRXS

Neuraxis Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $895.65K Miss $725.00M Estimate

JP Morgan analyst Ekaterina Knyazkova downgrades Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowers the price target from $45 to $30.

Downgrades

AMPH

JP Morgan Downgrades Amphastar Pharma to Neutral, Lowers Price Target to $30

<a href="https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18" title="https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18">https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18</a>

Biotech

General

GALT

Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Oncology, Developing Galectin-Based Therapeutics To Improve The Lives Of Patients With Chronic Liver Diseases And Cancer

JP Morgan analyst Chris Schott upgrades Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raises the price target from $21 to $23.

Upgrades

TEVA

JP Morgan Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $23

House Republicans on Sunday proposed a sweeping health-care overhaul that would slash about $880 billion from Medicaid to help finance $4.5 trillion in new and extended tax cuts championed by President Donald Trump.
What Happened: According to a <a href="https://www.washingtonpost.com/politics/2025/05/12/medicaid-cuts-trump-tax-cuts-bill/c5ae1ff2-2eea-11f0-8498-1f8214bba2d2_story.html">report</a> by The Washington Post, the legislation, described by GOP leaders as the "cost-saving centerpiece" of Trump's "big, beautiful bill," ignites the most consequential fight over U.S. health coverage since the failed 2017 Obamacare repeal push.
<h3 class="wp-block-heading">What The Bill Does</h3>
The 715-page Energy and Commerce section alone meets its $880 billion savings target by requiring able-bodied adults without dependents to log 80 hours a month of work, education, or service and verify eligibility twice a year. According <a href="https://apnews.com/article/medicaid-cuts-trump-tax-cuts-bill-1e2b12a91a3d12ceb0420ce7053de58e">to </a>the Associated Press, it also freezes state "provider taxes," ends a pandemic-era 5 percent funding bonus and bars federal dollars for Medicaid services to immigrants who lack citizenship proof.
See also: <a href="https://www.benzinga.com/25/05/45343633/tesla-battery-supplier-catl-to-raise-4-billion-through-hong-kong-listing-report">Tesla Battery Supplier CATL Eyes Over $4B In Hong Kong Listing — Could Become 2025&#8217;s Biggest IPO Yet</a>
<h3 class="wp-block-heading">What&#8217;s The Human impact?</h3>
A preliminary Congressional Budget Office score warns the changes would leave roughly <a href="https://www.benzinga.com/news/25/05/45307739/over-5-million-americans-risk-losing-health-coverage-by-2034-amid-proposed-gop-medicaid-cuts-cbo-fin">8.6 million fewer</a> people insured within a decade. Democrats call the package a fresh attempt to gut the Affordable Care Act, according to a separate ABC <a href="https://abcnews.go.com/Politics/wireStory/house-republicans-unveil-medicaid-cuts-democrats-warn-leave-121701684">report</a>. "In no uncertain terms, millions of Americans will lose their health-care coverage," said Rep. Frank Pallone of New Jersey.
<h3 class="wp-block-heading">What&#8217;s The GOP&#8217;s Argument?</h3>
Republicans counter that stricter screening will curb "waste, fraud and abuse" and free up cash to extend the expiring 2017 tax cuts. "Savings like these allow us to renew the Trump tax cuts and keep our promise to hardworking middle-class families," said Energy and Commerce Chair Brett Guthrie in a statement shared with ABC. The broader bill must identify at least $1.5 trillion in offsets to satisfy the party's budget blueprint.
Why It Matters: More than a dozen House Republicans from Medicaid-heavy districts have signaled they <a href="https://www.benzinga.com/personal-finance/25/03/44098458/if-a-bill-is-put-in-front-of-me-that-guts-benefits-i-will-not-vote-for-it-gop-faces-internal-divide-over-medicaid-cuts">cannot back</a> deep cuts, and Trump recently threatened to <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">veto any bill</a> that "touches" Medicaid benefits.
Even if the measure squeezes through the narrowly divided House, its prospects in the Senate are uncertain, with Democrats <a href="https://www.benzinga.com/markets/equities/25/05/45217098/trumps-big-beautiful-bill-takes-shape-gop-pushes-tax-cuts-border-wall-funding-and-deep-spending-reductions-ahead-of-memorial-day-deadline">unified against it</a> and several moderate Republicans uneasy.
Read next: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45343977/personal-finance-guru-ric-edelman-says-wall-streets-complex-products-take-young-investors-hostage-many-are-getting-their-financial-education-from-tiktok">Personal Finance Guru Ric Edelman Says Wall Street&#8217;s Complex Products Take Young Investors &#8216;Hostage&#8217;: &#8216;Many Are Getting Their Financial Education From TikTok&#8230;&#8217;</a>

Health Care

Trump's 'Big, Beautiful Bill' Banks On Huge Medicaid Cuts As Its 'Cost-Saving Centerpiece' — See Who Risks Losing Coverage Under The GOP Proposal

Jefferies analyst David Katz upgrades Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) from Hold to Buy and raises the price target from $228 to $296.

Jefferies Upgrades Hilton Worldwide Holdings to Buy, Raises Price Target to $296

BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) today announced that Robb A. LeMasters has stepped down from his position as executive vice president and chief financial officer. The company has named Mike T. Fitzgerald, current chief accounting officer, as the interim chief financial officer.
 &nbsp;

Management

BWXT

BWX Technologies CFO Robb LeMasters Steps Down; Appoints Mike Fitzgerald As Interim CFO

Needham analyst Bernie McTernan reiterates Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and maintains $27 price target.

Reiteration

SRAD

Needham Reiterates Buy on Sportradar Gr, Maintains $27 Price Target

Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) reported quarterly losses of $(0.21) per share. This is a 63.16 percent increase over losses of $(0.57) per share from the same period last year. The company reported $106.21 thousand in sales this quarter. This is a 412.36 percent increase over sales of $20.73 thousand the same period last year.

AIMD

Ainos Q1 EPS $(0.21) Up From $(0.57) YoY, Sales $106.21K Up From $20.73K YoY

Kilvinane Wind Farm to Generate 8,500 MWh Annually, Strengthening Ireland's Energy Grid and Sustainability Goals
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fameresco.com%2F&amp;esheet=54252403&amp;newsitemid=20250512305769&amp;lan=en-US&amp;anchor=Ameresco%2C+Inc.&amp;index=1&amp;md5=8923d4e903350cd8b488925bc9d82e29">Ameresco, Inc.</a>, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), a leading energy solutions provider dedicated to helping customers navigate the energy transition, today announced that its Irish subsidiary, Cork Sustainable Energy Limited (CSEL), has secured approval from An Bord Pleanála for a significant upgrade to the Kilvinane Wind Farm. This approval marks a pivotal step in enhancing Ireland's renewable energy infrastructure.
CSEL manages Kilvinane Wind Farm, located 8km East of Dunmanway, County Cork, which comprises of three turbines. The wind farm holds the capability to produce approximately 8,500 MWh of energy annually, supplying to the National Grid and contributing to Ireland's renewable energy targets as the second largest producer of wind energy in the world in terms of the share of electricity provided by wind energy.
An Bord Pleanála approved the wind farm upgrade, as it was designed to ensure consistency with the character of the structure and the neighboring structures. This decision provides greater clarity and certainty for wind farm operators and planning authorities regarding the planning implications of routine maintenance activities.

AMRC

Ameresco's Irish Subsidiary, Cork Sustainable Energy Limited Secures Approval To Upgrade Kilvinane Wind Farm, Enabling Annual Generation Of 8,500 MWh To Strengthen Ireland's National Grid And Advance Sustainability Goals

HC Wainwright &amp; Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and lowers the price target from $80 to $75.

GPCR

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $75

Jefferies analyst David Katz upgrades Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raises the price target from $226 to $303.

Jefferies Upgrades Marriott International to Buy, Raises Price Target to $303

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai&#x2122; platform, with a direct comparison to gold-standard wet-lab methods.
The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone.

ImmunoPrecise Announces Benchmarking Results For LENSai Epitope Mapping

WIIM

Sable Offshore shares are trading higher. The company reported Q1 financial results.

PSNY

Polestar Q1 Retail Sales 12,304 Cars, Up 76.5% YoY

<ul>
<li>Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. &nbsp;</li>
<li>IN8bio's proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. &nbsp;</li>
</ul>
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DB2yhXUoY-Ygc7UJXIHzObpDQdwo63iyjlW_wVNGtFk460i4jAnG6VXwX-4JfS1eebd9TRave9LWokSXv27QcA==">IN8bio, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new data on its proprietary γδ T manufacturing program. The oral presentation shared exciting updates about its unique manufacturing processes, including deep analytics, genomics and repertoire analysis, presented at the International Society for Cell &amp; Gene Therapy (ISCT) 2025 Annual Meeting. The data, which earned IN8bio the prestigious Host Region (U.S. East) Abstract Award, as presented by Bruce Levine, PhD, ISCT Past President and a member of IN8bio's Scientific Advisory Board. The award is a competitive recognition for scientific excellence and demonstrates how IN8bio's technology and know-how creates consistent, powerful cellular therapies.
The oral presentation highlights how IN8bio's DeltEx&#x2122;&nbsp;Allo manufacturing process consistently induces donor derived T cells to express γδ T cell receptors (TCRs) and genes, associated with increased cancer cytotoxicity. Gene expression profiling confirmed a highly potent product across multiple manufacturing batches.

INAB

IN8bio Wins ISCT Abstract Award For Analytical Characterization Of Its Gamma-Delta T Cell Therapies In INB-100 AML Trial, Demonstrating Durable Relapse-Free Survival And Showcasing Consistent, Potent Anti-Cancer Activity Through Its Proprietary DeltEx Allo Manufacturing Platform

Comments

IperionX

IperionX (IPX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌